The KCNH6 antibody is a research tool designed to target the KCNH6 protein, a member of the voltage-gated potassium (Kv) channel family encoded by the *KCNH6* gene. KCNH6. also known as Kv11.3 or HERG3. belongs to the ether-à-go-go (EAG) subfamily and plays a role in regulating cellular electrical activity by mediating potassium ion flux. Structurally, it contains six transmembrane domains and a cyclic nucleotide-binding homology domain, contributing to its function in repolarizing membranes in excitable cells. While its close homologs (e.g., KCNH2/Kv11.1) are well-studied in cardiac electrophysiology, KCNH6 is less characterized but is implicated in neuronal and endocrine systems, with emerging roles in cancer progression, metabolic disorders, and insulin secretion.
KCNH6 antibodies are primarily used in biomedical research to detect and quantify protein expression in tissues or cell lines via techniques like Western blotting, immunohistochemistry, or immunofluorescence. These antibodies help investigate KCNH6's physiological and pathological roles, such as its potential involvement in tumorigenesis or diabetes. Commercially available antibodies are often validated for specificity using knockout controls or peptide-blocking assays. However, researchers must verify cross-reactivity and batch consistency due to sequence similarities within the Kv family. Recent studies suggest KCNH6 may serve as a biomarker or therapeutic target, driving interest in developing high-affinity antibodies for functional studies and diagnostic applications.